On 13 January 2022, CJEU Advocate General Szpunar delivered his opinion in cases related to the practical necessity to re-box versus re-label parallel imported pharmaceuticals, following the implementation of the Falsified Medicines Directive.

AG Szpunar’s opinion would set the precedent for a new doctrine on intra-brand competition in the EU’s Internal Market writes our Secretary General, Kasper Ernest.

See the full analysis published on European Competition Law Review.